OncoMatch/Clinical Trials/NCT07126782
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
Is NCT07126782 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Ex-vivo expanded allogeneic γδ T cells for aml (acute myelogenous leukemia).
Treatment: Ex-vivo expanded allogeneic γδ T cells — The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells in patients with MRD-positive AML after allo-HSCT.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: allogeneic hematopoietic stem cell transplant
AML patients receiving allo-HSCT
Lab requirements
Blood counts
adequate bone marrow reserve, defined as: absolute neutrophil count (ANC) > 0.5E9/L and platelet count ≥20E9/L
Kidney function
severe renal disorders excluded
Liver function
severe hepatic disorders excluded
Cardiac function
LVEF >45%, NYHA Class I/II, QTc ≤480 msec, no clinically significant arrhythmias requiring medication
Adequate bone marrow reserve, defined as: absolute neutrophil count (ANC) > 0.5E9/L and platelet count ≥20E9/L. Adequate organ function as per protocol. Cardiac abnormalities, meeting any of the following: Left ventricular ejection fraction (LVEF) ≤45%. NYHA Class III/IV congestive heart failure. QTc interval >480 msec. Other cardiac conditions considered unsuitable by the investigator. severe hepatic, renal, or metabolic disorders.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07126782 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received allogeneic hematopoietic stem cell transplant.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages